Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany-Reference-Cited by-同舟云学术

Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany

Published:2022-07 Issue:7 Volume:6 Page:e736
ISSN:2572-9241
Container-title:HemaSphere
language:en
Short-container-title:

Author:

Skalt Daniela,Moertl Bernhard,von Bergwelt-Baildon Michael,Schmidt Christian,Schoel Wolfgang,Bücklein Veit,Weiglein Tobias,Dreyling Martin,Berger Karin

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hematology

Reference29 articles.

1. Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK’s Haematological Malignancy Research Network.;Smith;Br J Cancer,2015

2. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte.;Feugier;J Clin Oncol,2005

3. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.;Crump;Blood,2017

4. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial.;Mounier;Haematologica,2013

5. CAR T-cell product performance in haematological malignancies before and after marketing authorisation.;Elsallab;Lancet Oncol,2020

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Follicular lymphoma or diffuse large B-cell lymphoma: a population based analysis of epidemiological and health economic aspects in Germany;2024-09-03

2. Time‐dependent cost comparison and health economic impact analysis of second‐line interventions for transplant‐ineligible patients with relapsed or refractory diffuse large B cell lymphoma;European Journal of Haematology;2024-06-10

3. Cost-utility analysis of second-line axicabtagene ciloleucel versus standard of care in Japan based on the ZUMA-7 trial;Future Oncology;2024-06-05

4. La thérapie CAR : la place des institutions académiques dans leur production;Bulletin de l'Académie Nationale de Médecine;2024-05

5. Cost–effectiveness analysis 3L of axicabtagene ciloleucel vs tisagenlecleucel and lisocabtagene maraleucel in Japan;Future Oncology;2024-04-10